Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > VEGFA(Gene name) > Human
  • Add your favorite
  • VEGFA (Gene name),
  • Vascular endothelial growth factor A (Protein name ),  VEGFA_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Citations  (4)
  • |
  • Feedback
  • Gene name:
    VEGFA(VEGF);
    Protein name:
    Vascular endothelial growth factor A(VEGF-A);
    Alternative:
    Vascular permeability factor(VPF);
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Homodimer; disulfide-linked. Also found as heterodimer with PGF.
    Function:
    Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
    Subcellular Location:
    Secreted VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
    Protein Attributes:
    Sequence length:
    232
    Sequence:
    50:
    MNFLLSWVHW | SLALLLYLHH | AKWSQAAPMA | EGGGQNHHEV | VKFMDVYQRS | 
    100:
    YCHPIETLVD | IFQEYPDEIE | YIFKPSCVPL | MRCGGCCNDE | GLECVPTEES | 
    150:
    NITMQIMRIK | PHQGQHIGEM | SFLQHNKCEC | RPKKDRARQE | KKSVRGKGKG | 
    200:
    QKRKRKKSRY | KSWSVYVGAR | CCLMPWSLPG | PHPCGPCSER | RKHLFVQDPQ | 
    232:
    TCKCSCKNTD | SRCKARQLEL | NERTCRCDKP | RR
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    SMR:
    KEGG:
    String:
    UniGene:
    Pfam:
    MIM:
    Uniprot:
     
    FOR
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143c
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143d
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human VEGF-A
    Cat.:
    E0143b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143d
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human VEGF-A
    Cat.:
    U0143c
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human VEGF-A
    Cat.:
    P0143Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human VEGF-A
    Cat.:
    P0143Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human VEGF-A
    Cat.:
    P0143Rb-r
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human VEGF-A
    Polyclonal Antibody for Human VEGF-A
    Polyclonal Antibody for Human VEGF-A
    Polyclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Monoclonal Antibody for Human VEGF-A
    Protein for Human VEGF-A
    Protein for Human VEGF-A
    Protein for Human VEGF-A
    Protein for Human VEGF-A
    Protein for Human VEGF-A
    Protein for Human VEGF-A
    Protein for Human VEGF-A

    R&D Technical Data

        12% SDS-PAGE Analysis

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    s

    s
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤ 4.8%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤ 10.2%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤7.5%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤11.7%

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of VEGF-A into serum and plasma .

    Sample Type

    Average(%)

    Recovery  Range (%)

    Serum

    86

    80-95

    Plasma

    95

    90-102

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Recovery was determined by spiking various levels of VEGFA into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    103

    99-106

    Plasma

    102

    96-107

     

     

     

     

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of VEGF-A and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    84-93%

    79-94%

    88-96%

    78-91%

    EDTA plasma(n=5)

    78-89%

    82-97%

    90-102%

    89-103%

    heparin plasma(n=5)

    83-94%

     

    89-101%

    87-99%

    91-103%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of VEGFA and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    98-107%

    101-104%

    99-106%

    100-106%

    EDTA plasma(n=5)

    100-105%

    100-108%

    100-105%

    99-107%

    heparin plasma(n=5)

    97-109%

     

    99-106%

    95-110%

    100-105%

     

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Vascular endothelial growth factor is a secreted angiogenic mitogen."
      Leung D.W. , Cachianes G. , Kuang W.-J. , Goeddel D.V. , Ferrara N.
      Science246:1306-1309(1989) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS VEGF189 AND VEGF165)
    2. 2.
      "Vascular permeability factor, an endothelial cell mitogen related to PDGF."
      Keck P.J. , Hauser S.D. , Krivi G. , Sanzo K. , Warren T. , Feder J. , Connolly D.T.
      Science246:1309-1312(1989) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF189);PARTIAL PROTEIN SEQUENCE
    3. 3.
      "The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing."
      Tischer E. , Mitchell R. , Hartman T. , Silva M. , Gospodarowicz D. , Fiddes J.C. , Abraham J.A.
      J. Biol. Chem.266:11947-11954(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM VEGF189)
    4. 4.
      "The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA."
      Houck K.A. , Ferrara N. , Winer J. , Cachianes G. , Li B. , Leung D.W.
      Mol. Endocrinol.5:1806-1814(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM VEGF206)
    5. 5.
      "AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor."
      Weindel K. , Marme D. , Weich H.A.
      Biochem. Biophys. Res. Commun.183:1167-1174(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165)
    6. 6.
      "VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix."
      Poltorak Z. , Cohen T. , Sivan R. , Kandelis Y. , Spira G. , Vlodavsky I. , Keshet E. , Neufeld G.
      J. Biol. Chem.272:7151-7158(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF145)
    7. 7.
      "Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183."
      Lei J. , Jiang A. , Pei D.
      Biochim. Biophys. Acta1443:400-406(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF183)
      tissue: Kidney.
    8. 8.
      "Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability."
      Claffey K.P. , Shih S.-C. , Mullen A. , Dziennis S. , Cusick J.L. , Abrams K.R. , Lee S.W. , Detmar M.
      Mol. Biol. Cell9:469-481(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM L-VEGF165)
      tissue: Mammary gland.
    9. 9.
      "Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant."
      Whittle C.J. , Gillespie K.M. , Harrison R. , Mathieson P.W. , Harper S.J.
      Clin. Sci.97:303-312(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF148)
      tissue: Renal glomerulus.
    10. 10.
      "VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma."
      Bates D.O. , Cui T.-G. , Doughty J.M. , Winkler M. , Sugiono M. , Shields J.D. , Peat D. , Gillatt D. , Harper S.J.
      Cancer Res.62:4123-4131(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165B)
      tissue: Kidney.
    11. 11.
      "Human cDNA for the vascular endothelial growth factor isoform VEGF165."
      Murata H. , Fukushima J. , Hattori S. , Okuda K. , Yanagi H.
      Submitted (1998-12) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165)
      tissue: Hemangioendothelioma.
    12. 12.
      "Human cDNA for vascular endothelial growth factor isoform VEGF121."
      Sato J.D. , Whitney R.G.
      Submitted (1999-12) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF121)
    13. 13.
      "Cloning of vascular endothelial growth factor (VEGF) cDNA."
      Liu J. , Peng X. , Yuan J. , Qiang B.
      Submitted (2001-07) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165)
    14. 14.
      "Cloning and identification of vascular endothelial growth factor isoform VEGF165."
      Shan Z.X. , Yu X.Y. , Lin Q.X. , Fu Y.H. , Zheng M. , Tan H.H. , Lin S.G.
      Submitted (2002-02) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165)
      tissue: Heart.
    15. 15.
      "Cloning and characterization of VEGF from LNCaP cells, a line of prostate cancer cells."
      Koul S. , Johnson T. , Meacham R.B. , Koul H.K.
      Submitted (2004-09) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF165)
    16. 16.
      "VEGF111, a new VEGF-A variant lacking exons 5, 6 and 7."
      Mineur P.J. , Colige A.C. , Lambert C.A.
      Submitted (2005-10) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM VEGF111)
    17. 17.
      "Human protein factory for converting the transcriptome into an in vitro-expressed proteome."
      Goshima N. , Kawamura Y. , Fukumoto A. , Miura A. , Honma R. , Satoh R. , Wakamatsu A. , Yamamoto J. , Kimura K. , Nishikawa T. , Andoh T. , Iida Y. , Ishikawa K. , Ito E. , Kagawa N. , Kaminaga C. , Kanehori K. , Kawakami B. , more...
      Nat. Methods5:1011-1017(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM VEGF165)
    18. 18.
      "The DNA sequence and analysis of human chromosome 6."
      Mungall A.J. , Palmer S.A. , Sims S.K. , Edwards C.A. , Ashurst J.L. , Wilming L. , Jones M.C. , Horton R. , Hunt S.E. , Scott C.E. , Gilbert J.G.R. , Clamp M.E. , Bethel G. , Milne S. , Ainscough R. , Almeida J.P. , Ambrose K.D. , Andrews T.D. , more...
      Nature425:805-811(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    19. 19.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    20. 20.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM L-VEGF121)
      tissue: Lung.
    21. 21.
      SeattleSNPs variation discovery resource
      Submitted (2001-10) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 23-232
    22. 22.
      "Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells."
      Fiebich B.L. , Jaeger B. , Schoellmann C. , Weindel K. , Wilting J. , Kochs G. , Marme D. , Hug H. , Weich H.A.
      Eur. J. Biochem.211:19-26(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 27-41
    23. 23.
      "Signal peptide prediction based on analysis of experimentally verified cleavage sites."
      Zhang Z. , Henzel W.J.
      Protein Sci.13:2819-2824(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 27-41
    24. 24.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PRELIMINARY PROTEIN SEQUENCE OF 27-36; 43-50 AND 59-81
    25. 25.
      "Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor."
      Jingjing L. , Xue Y. , Agarwal N. , Roque R.S.
      Invest. Ophthalmol. Vis. Sci.40:752-759(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 114-209 (ISOFORM VEGF183)
      tissue: Retina.
    26. 26.
      "A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon."
      Tee M.K. , Jaffe R.B.
      Biochem. J.359:219-226(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ALTERNATIVE SPLICING (ISOFORMS L-VEGF121 AND L-VEGF165);PROCESSING;SUBCELLULAR LOCATION
    27. 27.
      "Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor."
      Murphy J.F. , Fitzgerald D.J.
      FASEB J.15:1667-1669(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION
    28. 28.
      "New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation."
      Huez I. , Bornes S. , Bresson D. , Creancier L. , Prats H.
      Mol. Endocrinol.15:2197-2210(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ALTERNATIVE SPLICING (ISOFORM L-VEGF189);PROCESSING;SUBCELLULAR LOCATION
    29. 29.
      "A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes."
      Awata T. , Inoue K. , Kurihara S. , Ohkubo T. , Watanabe M. , Inukai K. , Inoue I. , Katayama S.
      Diabetes51:1635-1639(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INVOLVEMENT IN MICROVASCULAR COMPLICATIONS OF DIABETES
    30. 30.
      "VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression."
      Woolard J. , Wang W.-Y. , Bevan H.S. , Qiu Y. , Morbidelli L. , Pritchard-Jones R.O. , Cui T.-G. , Sugiono M. , Waine E. , Perrin R. , Foster R. , Digby-Bell J. , Shields J.D. , Whittles C.E. , Mushens R.E. , Gillatt D.A. , Ziche M. , Harper S.J. , more...
      Cancer Res.64:7822-7835(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION (ISOFORM VEGF165B)
    31. 31.
      "Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences."
      Bornes S. , Boulard M. , Hieblot C. , Zanibellato C. , Iacovoni J.S. , Prats H. , Touriol C.
      J. Biol. Chem.279:18717-18726(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ALTERNATIVE SPLICING (ISOFORMS L-VEGF121; L-VEGF165 AND L-VEGF189)
    32. 32.
      "Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis."
      Rosenbaum-Dekel Y. , Fuchs A. , Yakirevich E. , Azriel A. , Mazareb S. , Resnick M.B. , Levi B.Z.
      Biochem. Biophys. Res. Commun.332:271-278(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ALTERNATIVE SPLICING (ISOFORMS L-VEGF121 AND L-VEGF165);PROCESSING;SUBCELLULAR LOCATION
    33. 33.
      "Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein."
      Dixelius J. , Olsson A.K. , Thulin A. , Lee C. , Johansson I. , Claesson-Welsh L.
      Cancer Res.66:2089-2097(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN CELL MIGRATION
    34. 34.
      "RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells."
      Shan B. , Gerez J. , Haedo M. , Fuertes M. , Theodoropoulou M. , Buchfelder M. , Losa M. , Stalla G.K. , Arzt E. , Renner U.
      Endocr. Relat. Cancer19:13-27(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: TISSUE SPECIFICITY;INDUCTION
    35. 35.
      "Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site."
      Muller Y.A. , Li B. , Christinger H.W. , Wells J.A. , Cunningham B.C. , de Vos A.M.
      Proc. Natl. Acad. Sci. U.S.A.94:7192-7197(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 34-135
    36. 36.
      "1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor."
      Fairbrother W.J. , Champe M.A. , Christinger H.W. , Keyt B.A. , Starovasnik M.A.
      Protein Sci.6:2250-2260(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: STRUCTURE BY NMR OF 34-135
    37. 37.
      "The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93-A resolution: multiple copy flexibility and receptor binding."
      Muller Y.A. , Christinger H.W. , Keyt B.A. , de Vos A.M.
      Structure5:1325-1338(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 34-135
    38. 38.
      "Crystal structure of the complex between VEGF and a receptor-blocking peptide."
      Wiesmann C. , Christinger H.W. , Cochran A.G. , Cunningham B.C. , Fairbrother W.J. , Keenan C.J. , Meng G. , de Vos A.M.
      Biochemistry37:17765-17772(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 39-134
    39. 39.
      "Solution structure of the heparin-binding domain of vascular endothelial growth factor."
      Fairbrother W.J. , Champe M.A. , Christinger H.W. , Keyt B.A. , Starovasnik M.A.
      Structure6:637-648(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: STRUCTURE BY NMR OF 137-215
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase Ubiquitin ELISA metalloproteinase Tumor necrosis Asprosin TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter